The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

This article gives an overview of the medications for cystic fibrosis. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a class of medications that help improve the ...

CF is caused by a mutation in the gene for the protein cystic fibrosis transmembrane conductance regulator (CFTR). This gene is required to regulate the components of sweat, digestive juices ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction ...

These granules, available in 25 mg, 50 mg, and 75 mg per unit dose packets, are a generic equivalent of Kalydeco Oral ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and often overlooked complication.

to introduce a healthy copy of the cystic fibrosis transmembrane conductance regulator (CFTR) gene into the cells of the lung. This method has already demonstrated high gene transfer efficiency ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and ...

Sionna Therapeutics is developing novel small molecule therapeutics for the treatment of cystic fibrosis. The company is headquartered in Waltham, Massachusetts, the US. For a complete picture of SION ...

It comprises of a recombinant chimeric adeno-associated virus vector (AV.TL65) encoding cystic fibrosis transmembrane conductance regulator (CFTR). The therapeutic candidate is developed based on the ...